FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to the production of subunit vaccines against Mycoplasma spp., and can be used in medicine to prevent the infection of Mycoplasma spp. Vaccine compositions based on the Tuf protein with SEQ ID NO were offered: 02 in combination with a pharmaceutically acceptable adjuvant, P46, MHP30 and NrdFC proteins and / or a pharmaceutically acceptable additive.
EFFECT: invention ensures the achievement of strong immune effects against Mycoplasma spp.
8 cl, 5 dwg, 4 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SUBUNIT VACCINE AGAINST MYCOPLASMA SPP | 2019 |
|
RU2759427C2 |
| COMPOSITION FOR PREVENTING AND TREATING MYCOPLASMA HYORHINIS INFECTION AND METHOD OF PRODUCING SAID COMPOSITION | 2020 |
|
RU2737971C1 |
| COMPOSITION FOR PREVENTING AND TREATING MYCOPLASMA HYORHINIS INFECTION AND METHOD OF PRODUCING SAID COMPOSITION | 2016 |
|
RU2724549C1 |
| VACCINE TO SWINE INFLUENZA A VIRUS | 2018 |
|
RU2787596C2 |
| TREATMENT AND PREVENTION OF ALLERGY TO HOUSE DUST MITES | 2019 |
|
RU2815386C2 |
| OPTIMIZED POLYPEPTIDE FOR A SUB-UNIT VACCINE FOR REOVIRUS OF BIRDS | 2017 |
|
RU2742250C2 |
| VACCINE COMPOSITION AGAINST INFECTION CAUSED BY STREPTOCOCCUS SUIS | 2015 |
|
RU2735101C2 |
| PORCINE PARVOVIRUS | 2015 |
|
RU2817872C2 |
| ANTIGENS AND ANTIGEN COMPOSITIONS | 2013 |
|
RU2727476C2 |
| THERAPEUTIC ANTI-CANCER NEOEPITOPE VACCINE | 2017 |
|
RU2782422C2 |
